← Back to Search

Phosphodiesterase-4 (PDE-4) Inhibitor

Crisaborole for Atopic Dermatitis

Phase 4
Waitlist Available
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at days 1, 8,15, 21 and 29
Awards & highlights

Study Summary

The purpose of this study is to document the timing of improvement in atopic dermatitis symptoms and severity following the application of crisaborole ointment 2% in patients 2 years or older with mild to moderate atopic dermatitis. Crisaborole ointment 2% will be applied topically twice daily for four weeks and progress will be assessed by photography and patient-reports.

Eligible Conditions
  • Atopic Dermatitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at days 1, 8,15, 21 and 29
This trial's timeline: 3 weeks for screening, Varies for treatment, and at days 1, 8,15, 21 and 29 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Time to success (by week) on ISGA
Time to success (in days) on ISGA

Trial Design

1Treatment groups
Experimental Treatment
Group I: CrisaboroleExperimental Treatment1 Intervention
Crisaborole is a low molecular weight benzoxaborole PDE-4 inhibitor for the treatment of mild-to-moderate atopic dermatitis in adults and children 2 years and above. Crisaborole ointment 2% is topically applied as a thin layer twice daily for 4 weeks to all AD lesions.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Crisaborole
FDA approved

Find a Location

Who is running the clinical trial?

PfizerIndustry Sponsor
4,582 Previous Clinical Trials
14,634,647 Total Patients Enrolled
Massachusetts General HospitalLead Sponsor
2,943 Previous Clinical Trials
13,200,839 Total Patients Enrolled
~29 spots leftby Jun 2025